Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

Ox­ford Bio­Ther­a­peu­tics said Thurs­day that it has ex­tend­ed its sec­ond col­lab­o­ra­tion with Boehringer In­gel­heim for an­oth­er two years. The biotech said that the ex­ten­sion will add more pro­grams to al­low for de­vel­op­ing “nov­el can­cer im­munother­a­pies” in in­di­ca­tions with a high­er un­met need.

The San Jose, CA-based biotech has been a part­ner with the pri­vate Ger­man phar­ma since 2013, when the com­pa­nies first inked an on­col­o­gy deal us­ing Ox­ford’s dis­cov­ery plat­form, called OGAP. The sec­ond deal was con­firmed in 2020 to dis­cov­er ad­di­tion­al se­lec­tive tar­gets for “strate­gic can­cer in­di­ca­tions,” again with Boehringer us­ing Ox­ford’s OGAP plat­form and com­bined with Boehringer’s T-cell en­gager, can­cer vac­cine and on­colyt­ic virus plat­forms.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN